- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
UGqr. Yu Baofa kunye neqela elivela e-United States bapapasha inqaku kwi-Journal ye-Gastroenterology Research and Practice
2025-02-11
UGqirha Yu Baofa kunye neqela laseMelika ngokudibeneyo bapapashe inqaku loVavanyo lwee-autoantibodies ezininzi kwi-tumor ehambelana ne-antigens njengeempawu zokuxilonga ezinokubakho zomhlaza wepancreatic kwiJenali yeGastroenterology Research and Practice.
Injongo yolu phononongo yayikukuvavanya ukubaluleka kweklinikhi ye-autoantibodies ngokuchasene ne-GNA11, i-MSLN, i-GNAS, i-CEBPA, i-MDM2, i-p16, i-Sui1, i-Calnuc, i-PTEN kwi-cancer ye-pancreatic (PC). Iisampuli ze-serum ze-33 ezivela kwizigulane ze-PC kunye neesampuli ze-serum ze-45 ezivela kulawulo oluqhelekileyo (NC) zibandakanyiwe, kunye neentlobo ze-9 ze-autoantibodies zifunyenwe zisebenzisa i-enzyme-linked immunosorbent assay (ELISA). Vavanya usebenzisa iiparameters ezininzi kumntu ngamnye okanye kwifom edibeneyo. Ngaphandle kwe-anti GNAS kunye ne-anti calNUC, amanqanaba azo zonke ezinye ii-autoantibodies ayephezulu kakhulu kunalawo akwiqela eliqhelekileyo lokulawula. Xa kuthelekiswa neqela eliqhelekileyo lokulawula (4.9%), i-frequencies ye-autoantibodies ezine, i-MSLN, i-p16, i-PTEN, kunye ne-Sui1, yanda kakhulu, kwi-75.8%, 66.7%, 30.3%, kunye ne-27.3%, ngokulandelanayo. Ukukwazi kwezi autoantibodies ukwahlula indawo phantsi kwe-ROC curve (AUC) ukusuka kwi-0.666 ukuya kwi-0.884, kunye ne-anti-p16 (i-AUC ye-0.884) kunye ne-anti MSLN (i-AUC ye-0.857) ebonisa ukusebenza okunamandla okuxilonga. Ukuhlanganiswa kwe-anti-MSLN kunye ne-anti-p16 kunokuphucula ukuvakalelwa kokuxilongwa.
Ukongeza, zombini i-MSLN kunye ne-Sui1 autoantibodies zehla kwizigulana ze-PC emva kwechemotherapy. Ii-autoantibodies ezine ezichasene ne-MSLN, i-p16, i-Sui1 kunye ne-PTEN zibonise iimpawu ezinokubakho zokuxilonga umhlaza we-pancreatic, apho i-anti MSLN kunye ne-anti p16 yayiyeyona ilungileyo. Udibaniso lwezi zithinteli-gazi zimbini zibonisa ezona zinto zinoqoqosho nezisebenzayo. Ukubaluleka kokuhla kwe-autoantibodies ngokuchasene ne-MSLN kunye ne-Sui1 kwizigulane ze-PC emva kwe-chemotherapy ifuna ukuphononongwa ngakumbi.
Uphando malunga ne-autoantibodies enxulumene ne-tumor ibonelela ngereferensi ebalulekileyo yokuvavanywa kwangoko, ukuxilongwa, kunye nonyango lwamathumba. Isifundiswa uYu Baofa wasebenzisa amajoni omzimba kwithumba kunyango lwethumba ngaphezulu kweminyaka engama-20 eyadlulayo.
